Mike Kratky
Stock Analyst at Leerink Partners
(2.73)
# 1,828
Out of 5,128 analysts
35
Total ratings
45.45%
Success rate
32.35%
Average return
Main Sectors:
Stocks Rated by Mike Kratky
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BSX Boston Scientific | Maintains: Outperform | $127 → $128 | $98.65 | +29.75% | 2 | Oct 1, 2025 | |
| INSP Inspire Medical Systems | Maintains: Market Perform | $116 → $97 | $99.03 | -2.05% | 7 | Aug 15, 2025 | |
| MDT Medtronic | Initiates: Outperform | $110 | $99.77 | +10.25% | 1 | Jun 16, 2025 | |
| BBNX Beta Bionics | Initiates: Outperform | $28 | $31.49 | -11.08% | 1 | Feb 24, 2025 | |
| TXG 10x Genomics | Downgrades: Market Perform | $25 → $12 | $19.99 | -39.97% | 2 | Feb 13, 2025 | |
| DXCM DexCom | Maintains: Outperform | $90 → $87 | $70.10 | +24.11% | 2 | Oct 25, 2024 | |
| PEN Penumbra | Initiates: Outperform | $263 | $316.15 | -16.81% | 1 | Sep 3, 2024 | |
| TNDM Tandem Diabetes Care | Upgrades: Outperform | $34 → $45 | $22.71 | +98.15% | 2 | Apr 25, 2024 | |
| NPCE NeuroPace | Initiates: Outperform | $22 | $16.80 | +30.95% | 1 | Jan 30, 2024 | |
| PODD Insulet | Initiates: Outperform | $184 | $299.17 | -38.50% | 1 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $42 | $40.35 | +4.09% | 1 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $342 | $592.27 | -42.26% | 1 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $75 | $84.83 | -11.59% | 1 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $37 | $33.92 | +9.08% | 1 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $9 | $32.95 | -72.69% | 1 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $325 → $50 | $21.00 | +138.10% | 2 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $33 → $45 | $1.35 | +3,233.33% | 2 | Jan 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $145 → $315 | $561.13 | -43.86% | 1 | Dec 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $26 → $31 | $76.69 | -59.58% | 2 | Dec 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $12 → $14 | $26.73 | -47.62% | 1 | Nov 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $32 → $40 | $30.57 | +30.85% | 1 | Aug 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $392 → $384 | $32.42 | +1,084.45% | 1 | Aug 11, 2022 |
Boston Scientific
Oct 1, 2025
Maintains: Outperform
Price Target: $127 → $128
Current: $98.65
Upside: +29.75%
Inspire Medical Systems
Aug 15, 2025
Maintains: Market Perform
Price Target: $116 → $97
Current: $99.03
Upside: -2.05%
Medtronic
Jun 16, 2025
Initiates: Outperform
Price Target: $110
Current: $99.77
Upside: +10.25%
Beta Bionics
Feb 24, 2025
Initiates: Outperform
Price Target: $28
Current: $31.49
Upside: -11.08%
10x Genomics
Feb 13, 2025
Downgrades: Market Perform
Price Target: $25 → $12
Current: $19.99
Upside: -39.97%
DexCom
Oct 25, 2024
Maintains: Outperform
Price Target: $90 → $87
Current: $70.10
Upside: +24.11%
Penumbra
Sep 3, 2024
Initiates: Outperform
Price Target: $263
Current: $316.15
Upside: -16.81%
Tandem Diabetes Care
Apr 25, 2024
Upgrades: Outperform
Price Target: $34 → $45
Current: $22.71
Upside: +98.15%
NeuroPace
Jan 30, 2024
Initiates: Outperform
Price Target: $22
Current: $16.80
Upside: +30.95%
Insulet
Oct 16, 2023
Initiates: Outperform
Price Target: $184
Current: $299.17
Upside: -38.50%
Oct 16, 2023
Initiates: Outperform
Price Target: $42
Current: $40.35
Upside: +4.09%
Oct 16, 2023
Initiates: Outperform
Price Target: $342
Current: $592.27
Upside: -42.26%
Oct 16, 2023
Initiates: Market Perform
Price Target: $75
Current: $84.83
Upside: -11.59%
Oct 16, 2023
Initiates: Outperform
Price Target: $37
Current: $33.92
Upside: +9.08%
Oct 16, 2023
Initiates: Outperform
Price Target: $9
Current: $32.95
Upside: -72.69%
Aug 15, 2023
Downgrades: Market Perform
Price Target: $325 → $50
Current: $21.00
Upside: +138.10%
Jan 24, 2023
Maintains: Outperform
Price Target: $33 → $45
Current: $1.35
Upside: +3,233.33%
Dec 20, 2022
Maintains: Outperform
Price Target: $145 → $315
Current: $561.13
Upside: -43.86%
Dec 15, 2022
Maintains: Market Perform
Price Target: $26 → $31
Current: $76.69
Upside: -59.58%
Nov 4, 2022
Maintains: Outperform
Price Target: $12 → $14
Current: $26.73
Upside: -47.62%
Aug 15, 2022
Maintains: Outperform
Price Target: $32 → $40
Current: $30.57
Upside: +30.85%
Aug 11, 2022
Maintains: Outperform
Price Target: $392 → $384
Current: $32.42
Upside: +1,084.45%